Description
Respiratory trials are the most expensive and time consuming of all therapeutic areas—47% more than oncology trials and 80% more than cardiovascular trails (source: HHS, Figure 3).
In this conversation with Dr. Castro, we explore the reasons behind the high costs of respiratory trials, conventional endpoints for these trials, and how imaging biomarkers are being used to improve the situation.
Listeners are left with an understanding of the increasing role of imaging in respiratory trials, key biomarkers, and promising new therapies and validation metrics on the horizon.
Highlights
Dr. Castro on the sensitivity of imaging biomarker endpoints
“We have a lot of patients where their lung function doesn’t change much, yet we see progression in their imaging biomarkers.”
What imaging biomarkers are you using in ILD trials?
Watch the Full Webinar
Access the full webinar for much more, including:
- Mucus plugging and asthma
- The role of the FDA in imaging biomarkers for clinical trials
- The impact of COVID-19 on our population
- The consideration of radiation in imaging trials
Speaker Bios
Mario Castro, MD, MPH
E. Phillips and Lenora Carr Phillips Professor
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers Clinical and Translational Science Institute at the University of Kansas
University of Kansas School of Medicine
Dr. Castro is a Professor of Medicine, Vice Chair for Clinical and Translational Research, Department of Medicine, Chief, Division of Pulmonary, Critical Care and Sleep Medicine at University of Kansas Medical Center (KUMC), and Director of the Frontiers: University of Kansas Clinical and Translational Science Institute and Adjunct Research Professor at the University of Missouri-Kansas City School of Medicine. He has been a leader of the CDC Controlling Asthma in American Cities, American Lung Association Airway Clinical Research Centers, and NHLBI Asthma Clinical Research Network, Severe Asthma Research Program, AsthmaNet and PrecISE research networks. His translational research projects in the Asthma and Airway Translational Research Unit (AATRU) are focused on the pathogenesis of asthma and treatment of asthma, especially in severe disease. Recently, Dr. Castro has spearheaded several initiatives to combat the COVID-19 pandemic: Lead investigator for NIH/NIAID-funded COVID-19 Prevention Trials Network (CoVPN trial), ACTIV-2 trial and the PCORNET HERO HCQ trial. He is the author of over 30 chapters/books and over 300 peer-reviewed articles; over the past 25+ years, Dr. Castro has trained over 40 junior clinical & translational scholars. He is widely recognized as an expert clinician, an excellent mentor, and skilled educator with a significant commitment to the development of young investigator’s careers.